title: [The Safety of Super-Selective Intra-Arterial Infusion Chemotherapy for Induction with Docetaxel, Cisplatin, and 5-Fluorouracil for Oral Cancer].
abstract: Adverse events and complications were retrospectively evaluated in 13 oral cancer patients receiving 3-drug, super-selective, intra-arterial infusion induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (GroupA ), and another 13 patients receiving systemic chemotherapy (GroupB ). As a systemic adverse event, neutropenia was significantly milder in GroupA than in GroupB (p=0.043). However, among local adverse events, the incidence rates of oral mucous membrane disorders were 69.2% (9 patients) in GroupA and 23.1% (3 patients)in GroupB, and therefore significantly higher in Group A(p=0.021). No significant difference was observed between the two groups considering the time of onset of oral mucous membrane disorders. Among complications, there were no cerebral infarctions, but facial palsy occurred in 1 patient. Thus, in a comparison between adverse events associated with super-selective intra-arterial infusion induction chemotherapy for oral cancer and systemic chemotherapy, the former showed milder neutropenia and a trend toward milder systemic adverse events. However, the incidence rate of oral mucositis as a local adverse event was significantly higher. For super-selective intra-arterial infusion chemotherapy, it appears to be important to prevent oral mucositis and to control the risks of complications such as facial palsy and cerebral infarction.
authors.affiliation: Dept. of Pharmacy, Fujita Health University Banbuntane Houtokukai Hospital.
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Hiraiwa
authors.forename: Mayu
authors.initials: M
authors.lastname: Koike
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Senda
authors.forename: Kenji
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D060828:Induction Chemotherapy; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil